Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of AMT-116 and AMT-253 CAR-T cells in advanced squamous cancers and melanoma
ChiCTR1900027852Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Feb 2020
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of AMT-116 CAR-T and AMT-253 CAR-T cells in Pulmonary squamous cell carcinoma, head and neck squamous cell carcinoma (HNSCC) and melanoma (3 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Dose-limiting toxicity. Planned start Feb 2020; status: not yet recruiting.
02
Drugs
AMT-116 CAR-TAMT-253 CAR-T cells
03
Conditions
Pulmonary squamous cell carcinomahead and neck squamous cell carcinoma (HNSCC)melanoma
Beyond the preview
Go deeper on ChiCTR1900027852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900027852.